PA8786101A1 - "DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA" - Google Patents

"DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA"

Info

Publication number
PA8786101A1
PA8786101A1 PA20088786101A PA8786101A PA8786101A1 PA 8786101 A1 PA8786101 A1 PA 8786101A1 PA 20088786101 A PA20088786101 A PA 20088786101A PA 8786101 A PA8786101 A PA 8786101A PA 8786101 A1 PA8786101 A1 PA 8786101A1
Authority
PA
Panama
Prior art keywords
group
groups
eventually replaced
piridin
imidazo
Prior art date
Application number
PA20088786101A
Other languages
English (en)
Inventor
Philippe Burnier
Pascal George
Adrien Tak Li
Frederic Puech
Matthieu Barrague
Zhongli Gao
Roy Vaz
Qiuxia Zhao
Cecile Enguehard
Alain Gueiffier
Garcia Antonio Almario
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PA8786101A1 publication Critical patent/PA8786101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCIÓN SE REFIERE A DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL)IMIDAZO[1,2-B]PIRIDAZINA, QUE RESPONDEN A LA FÓRMULA GENERAL ( I ) EN LA QUE : -R2 REPRESENTA UN GRUPO ARILO EVENTUALMENTE SUSTITUIDO CON UNO O VARIOS SUSTITUYENTES ELEGIDOS ENTRE ÁTOMOS DE HALÓGENO Y GRUPOS ALQUILO(C1-C6), ALCOXI(C1-C6), ALQUILTIO(C1-C6), FLUOROALQUILO(C1-C6), FLUOROALCOXI(C1-C6), -CN ; R3 REPRESENTA UN ÁTOMO DE HIDRÓGENO O UN GRUPO ALQUILO(C1-C3), -NR4R5, HIDROXILO O ALCOXI(C1-C4) ; -A REPRESENTA UN GRUPO ALQUILENO(C1-C7) EVENTUALMENTE SUSTITUIDO CON UNO O DOS GRUPOS RA ; B REPRESENTA UN GRUPO ALQUILENO(C1-C7) EVENTUALMENTE SUSTITUIDO CON UN GRUPO RB ; L REPRESENTA, O UN ÁTOMO DE NITRÓGENO EVENTUALMENTE SUSTITUIDO CON UN GRUPO RC O RD, O UN ÁTOMO DE CARBONO SUSTITUIDO CON UN GRUPO RE1 Y UN GRUPO RD O DOS GRUPOS RE2 ; ESTANDO LOS ÁTOMOS DE CARBONO DE A Y DE B O LOS GRUPOS RE2 EVENTUALMENTE SUSTITUIDOS CON UNO O VARIOS GRUPOS RF IDÉNTICOS O DIFERENTES UNO DE OTRO ; - R7 Y R8 REPRESENTAN, INDEPENDIENTEMENTE UNO DE OTRO, UN ÁTOMO DE HIDRÓGENO O UN GRUPO ALQUILO(C1-C6). PROCEDIMIENTO DE PREPARACIÓN Y APLICACIÓN EN TERAPÉUTICA.
PA20088786101A 2007-06-28 2008-06-27 "DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA" PA8786101A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94678507P 2007-06-28 2007-06-28
FR0704661A FR2918061B1 (fr) 2007-06-28 2007-06-28 Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.

Publications (1)

Publication Number Publication Date
PA8786101A1 true PA8786101A1 (es) 2009-01-23

Family

ID=39203151

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088786101A PA8786101A1 (es) 2007-06-28 2008-06-27 "DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA"

Country Status (22)

Country Link
US (2) US8354405B2 (es)
EP (1) EP2170889B1 (es)
JP (1) JP5537424B2 (es)
KR (1) KR20100050492A (es)
CN (1) CN101765602A (es)
AR (1) AR069269A1 (es)
AU (1) AU2008281662A1 (es)
BR (1) BRPI0814807A2 (es)
CA (1) CA2691866A1 (es)
CL (1) CL2008001932A1 (es)
CO (1) CO6251269A2 (es)
EA (1) EA201070072A1 (es)
FR (1) FR2918061B1 (es)
MA (1) MA31572B1 (es)
MX (1) MX2009013948A (es)
NZ (1) NZ582677A (es)
PA (1) PA8786101A1 (es)
PE (1) PE20090556A1 (es)
TW (1) TW200911812A (es)
UY (1) UY31193A1 (es)
WO (1) WO2009016286A2 (es)
ZA (1) ZA200909186B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US8507488B2 (en) 2008-05-13 2013-08-13 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
FR2934994B1 (fr) * 2008-08-12 2010-09-17 Sanofi Aventis Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique
FR2939134A1 (fr) * 2008-12-01 2010-06-04 Sanofi Aventis Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2940285A1 (fr) * 2008-12-19 2010-06-25 Sanofi Aventis Derives de 6-cycloamino-2-thienyl-3-(pyridin-4-yl)imidazo °1,2-b!-pyridazine et 6-cycloamino-2-furanyl-3- (pyridin-4-yl)imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
CN102781942B (zh) 2009-10-23 2015-09-23 詹森药业有限公司 用作食欲肽受体调节剂的二取代八氢吡咯并[3,4-c]吡咯
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CA2795765C (en) 2010-04-06 2020-07-07 Fred Hutchinson Cancer Research Center Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
CA2818903C (en) * 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
TWI617559B (zh) * 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
CN103619846B (zh) 2011-06-27 2016-08-17 詹森药业有限公司 1-芳基-4-甲基-[1,2,4]三唑[4,3-a]喹喔啉衍生物
EP3778896A1 (en) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
CN104411312B (zh) 2012-06-26 2018-03-06 詹森药业有限公司 包括pde2抑制剂例如1‑芳基‑4‑甲基‑[1,2,4]三唑[4,3‑a]‑喹喔啉化合物和pde10抑制剂的用于在治疗神经病学障碍或代谢障碍中使用的组合
AU2013283318B2 (en) 2012-06-27 2017-11-23 4Sc Ag Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders
ES2607184T3 (es) 2012-07-09 2017-03-29 Janssen Pharmaceutica, N.V. Inhibidores de la enzima fosfodiesterasa 10
CZ2012538A3 (cs) * 2012-08-08 2014-02-19 Masarykova Univerzita Inhibitory pro léčbu B-buněčné chronické lymfocytární leukémie
US10676746B2 (en) 2013-11-22 2020-06-09 Fred Hutchinson Cancer Research Center Methods for identifying therapeutic targets and treating monitoring cancers
RU2016132574A (ru) * 2014-01-09 2018-02-12 Интра-Селлулар Терапиз, Инк. Органические соединения
US20170042893A1 (en) * 2014-02-03 2017-02-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of casein kinase i inhibitors for depleting stem cells
CR20180433A (es) 2016-03-10 2018-11-07 Janssen Pharmaceutica Nv Métodos para tratar la depresión con antagonistas del receptor de orexina-2
HUE063830T2 (hu) 2017-03-14 2024-02-28 Daiichi Sankyo Co Ltd Eljárás 3,6-diszubsztituált imidazo[1,2-b]piridazin származék elõállításához
SI3448859T1 (sl) 2017-03-20 2020-02-28 Forma Therapeutics, Inc. Sestavki pirolopirola kot aktivatorji piruvat kinaze (PKR)
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
CN111471056B (zh) * 2019-01-23 2021-07-02 成都先导药物开发股份有限公司 一种大环类免疫调节剂
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
US11193891B2 (en) 2019-12-20 2021-12-07 Robert Bosch Gmbh Receptors and spacers for a fluorescence-based lead ion chemosensor
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
US20230192699A1 (en) * 2020-03-27 2023-06-22 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
IL312114A (en) 2021-10-14 2024-06-01 Incyte Corp Quinoline compounds as Kras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103926D0 (en) * 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
CN100439367C (zh) * 2003-12-11 2008-12-03 安万特药物公司 作为酪蛋白激酶Iε抑制剂的取代的1H-吡咯并[3,2-b、3,2-c和2,3-c]吡啶-2-甲酰胺以及相关类似物
JP4972804B2 (ja) * 2004-08-31 2012-07-11 Ｍｓｄ株式会社 新規置換イミダゾール誘導体
WO2006070943A1 (ja) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
JP2009502734A (ja) * 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
JP5357763B2 (ja) * 2006-11-06 2013-12-04 トレロ ファーマシューティカルズ， インコーポレイテッド イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用
AR064420A1 (es) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).

Also Published As

Publication number Publication date
US20130012516A1 (en) 2013-01-10
JP2010531342A (ja) 2010-09-24
AU2008281662A1 (en) 2009-02-05
PE20090556A1 (es) 2009-06-01
US20100179154A1 (en) 2010-07-15
UY31193A1 (es) 2009-01-30
MA31572B1 (fr) 2010-08-02
AR069269A1 (es) 2010-01-13
CN101765602A (zh) 2010-06-30
MX2009013948A (es) 2010-03-09
EA201070072A1 (ru) 2010-08-30
EP2170889A2 (fr) 2010-04-07
US8846676B2 (en) 2014-09-30
CO6251269A2 (es) 2011-02-21
US8354405B2 (en) 2013-01-15
CL2008001932A1 (es) 2009-09-25
KR20100050492A (ko) 2010-05-13
BRPI0814807A2 (pt) 2015-02-03
JP5537424B2 (ja) 2014-07-02
FR2918061B1 (fr) 2010-10-22
NZ582677A (en) 2011-12-22
ZA200909186B (en) 2011-02-23
WO2009016286A3 (fr) 2009-04-09
TW200911812A (en) 2009-03-16
EP2170889B1 (fr) 2016-08-17
FR2918061A1 (fr) 2009-01-02
WO2009016286A2 (fr) 2009-02-05
CA2691866A1 (fr) 2009-02-05

Similar Documents

Publication Publication Date Title
PA8786101A1 (es) "DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA"
CO6290690A2 (es) Derivados de la 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]-piridazina su preparacion y su aplicacion en terapeutica
CO6280508A2 (es) Derivados de carboxamidas n-azabicliclicas su preparacion y su aplicacion en terapeutica
NI201000124A (es) Derivados de carboxamidas azabicíclicas, su preparación y su aplicación en terapéutica
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
CY1113764T1 (el) Βενζοϊκου οξεος (1-φαινυλ-2-πυριδιν-4-υλ) αιθυλ εστερες ως αναστολεις φωσφοδιεστερασης
ECSP13012771A (es) Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos
HN2010001460A (es) Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion terapeutica
BR122019003178B1 (pt) método de controle de pestes
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
AR070221A1 (es) Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
BR112015032689A2 (pt) composto heterocíclico fundido e uso em controle de pragas do mesmo
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
CR8889A (es) Derivados de n-(1h-indolil)- 1h-indol-2- carboxamidas, su preparacion y su aplicacion en terapeutica
ECSP088105A (es) Derivados de n-(arilalquil)-1h-pirrolopiridin-2-carboxamidas, su preparación y su aplicación en terapéutica
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR066605A1 (es) Derivados de heteroarilamida pirimidona
GT200500319A (es) Algunos metabolitos derivados de [1,4]diazepino[6,7,1-ij]quinolina y metodos para la preparacion y usos de los mismos.
BR112021018692A2 (pt) 1,1-dióxido de isotiazolidina e 1,4-butanossultona contendo derivados de rapamicina e usos dos mesmos
PA8854501A1 (es) "DERIVADOS DE 6-CICLOAMINO-2-TIENTI-3-(PIRINDIN-4-IL)IMIDAZO(1,2-B)-PIRIDAZINA Y 6-CICLOAMINO-2-FURANIL-3-(PIRIDIN-4-IL)IMIDAZO)1,2-b)-PIRIDAZINA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPEUTICA."
ES2194692T3 (es) Derivados de dihidro-furo-(3,4-b)-quinolein-1-onas, su procedimiento de preparacion y las composiciones farmceuticas que los contienen.
CO6290668A2 (es) Derivados de 1-oxo-1,2-dihidroisoquinolein-5-carboxamidas y de 4-oxo-3,4-dihifroquinazolina -8-carboxamidas su preparacion y su aplicacion en terapeutica
ECSP066810A (es) Derivados de carbamato de 2h- ó 3h-benzo[e]indazol-1-ilo, su preparación y su aplicación en terapéutica